LifeSprout, Inc.

LifeSprout, Inc. is a biotechnology company founded in 2015 with the slogan "Revolutionary Products for Soft Tissue Replacement and Regeneration." The company is based in the United States and is focused on developing groundbreaking products for aesthetic and regenerative medicine. Leveraging recent advances in materials science, LifeSprout has created a platform that mimics the body’s own tissues. This platform is being utilized to develop a suite of products catering to millions of patients annually with soft tissue losses due to aging, cancer, and metabolic disease. The company's next-generation products aim to enhance form and function with minimal downtime and exceptional results. LifeSprout recently received a significant financial backing with a $28.50M Series A investment on 27 April 2020. The investment was made by a consortium of prominent investors including Camden Partners, Redmile Group, Emerald Development Managers, Nexus Capital Management, Triskelion Capital, and the Abell Foundation. These investments reflect the strong potential and market demand for LifeSprout’s innovative approach to soft tissue replacement and regeneration within the biotechnology and healthcare industries.